Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease

Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.

Corresponding Author: Charalampos Tzoulis, PhD, Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Department of Clinical Medicine, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway (charalampos.tzoulis@uib.no).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.